Rafael pharmaceuticals to present new pancreatic cancer and biliary tract cancer data featuring cpi-613® (devimistat) at the american society of clinical oncology (asco) 2021 virtual scientific program

Cranbury, n.j., may 26, 2021 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 american society of clinical oncology (asco) annual meeting, taking place june 4-8, 2021. these presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer.
RFL Ratings Summary
RFL Quant Ranking